GENE ONLINE|News &
Opinion
Blog

Beta-thalassemia
Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval
2024-01-18
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
64th ASH Annual Meeting and Exposition: Discoveries That Reinvent Blood Disease Treatments
2022-12-20
Bluebird Bio’s Zynteglo Becomes First FDA-Approved Gene Therapy For Beta-Thalassemia
2022-08-18
CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label
2022-04-27
FDA Grants Priority Review for bluebird bio’s β-Thalassemia Gene Therapy
2021-11-23
Vertex to Reap Majority Profits from Gene Editing Deal with CRISPR Therapeutics
2021-04-21
GeneOnline’s Top 10 Headlines of the Year
2020-12-30
CRISPR Gene-Edited Therapy CTX001 Raises Hopes for Sickle Cell Disease and β-Thalassemia Cures
2020-12-07
CRISPR/Cas9 Gene Editing in Cell and Gene Therapies
2020-11-08
CRISPR, Vertex’s Gene Editing Based Therapy, CTX001 Prospers in Hemoglobinopathy Trials
2020-06-18
Celgene, Acceleron’s novel anemia drug gets FDA green light for rare blood disorder
2019-11-11
LATEST
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top